Affiliation:
1. Department of Cell & Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, SC 29425, USA
Abstract
Abstract
Although the bioflavonoids, a large group of polyphenolic natural products, exert chemopreventive effects in cardiovascular disease and cancer, there is little information about the disposition of these dietary components in man. The objective of this study was to investigate the plasma-protein binding of the most abundant bioflavonoid, quercetin, using 14C-labelled quercetin.
An ultracentrifugation assay (170 000 g for 16 h at 20°C) was shown to sediment plasma proteins. Binding of quercetin to normal plasma was extensive (99.1 ± 0.5%, mean ± s.d., n = 5). The unbound fraction varied as much as 6-fold, 0.3–1.8%, between subjects. This high binding was independent of quercetin concentration over the range 1.5–15 μM (0.5–5 μg mL−1). Human serum albumin was the primary protein responsible for the binding of quercetin in plasma (99.4 ± 0.1%). Binding by α1-acid glycoprotein (39.2 ± 0.5%) and very-low-density lipoproteins (< 0.5% of total quercetin) did not make substantial contributions to overall plasma binding. The equilibrium association constant for the binding of quercetin to serum albumin was 267 ± 33 times 103 M−1 (n=15). Thermodynamic data for the binding of quercetin to serum albumin indicated spontaneous, endothermic association. Displacement studies suggested that in man the ‘IIA’ subdomain binding site of human serum albumin was the primary binding site for quercetin. Association of quercetin with erythrocytes was significantly (P < 0.001) reduced by plasma protein binding.
These data indicate poor cellular availability of quercetin because of its extensive binding to plasma proteins.
Funder
National Institutes of Health
Publisher
Oxford University Press (OUP)
Subject
Pharmaceutical Science,Pharmacology
Reference24 articles.
1. The causes and prevention of cancer;Ames;Proc. Natl Acad. Sci.,1995
2. Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources;Cook;Nutr. Biochem.,1996
3. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase;De Azevedo;Proc. Natl Acad. Sci.,1996
4. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition;Ferry;Clin. Cancer Res.,1996
5. Review of the biology of quercetin and related bioflavonoids;Formica;Food Chem. Toxicol.,1995
Cited by
181 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献